Phase 2 Peripheral Neuropathy Trial, Recruiting NCT07396376 Sponsor: Eluciderm Inc Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Phase 2 Peripheral Neuropathy Trial, Recruiting

NCT07396376
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old
  • You have been diagnosed with either type 1 or type 2 diabetes
  • Your recent blood sugar control measure (called A1C) is 10 or below, based on a test taken within the last 2 months
  • Your body mass index (a measure of body weight relative to height) is 36 or below
  • You have a diabetic foot ulcer (wound on the foot) of a specific moderate severity, and after wound cleaning, the wound measures between 1.0 and 8.0 square centimetres
  • Your foot wound has been present for between 4 and 52 weeks
  • Your foot wound is located at least 1 centimetre below the ankle bone
  • Tests show that blood is flowing adequately to your foot (confirm with trial site)
  • If you have a wound on the sole of your foot, you must have been using an offloading device (something to take pressure off the wound) for at least 14 days before starting treatment
  • You are able to give your consent to take part and attend all required appointments
  • If you are a woman who could become pregnant, you must meet the trial's contraception requirements (confirm with trial site)

Who may not be able to join:

  • Your foot wound is currently infected, or the skin around it is infected
  • Your wound is caused by poor blood supply, or you have a bone infection or exposed bone
  • You have recently needed antibiotics for an active infection (you may become eligible after the infection clears and a 7-day waiting period has passed)
  • You have an active or unstable Charcot foot condition that prevents you from using an offloading device
  • Your haemoglobin (a measure of red blood cells) is below 10 g/dL, unless the trial sponsor gives special approval
  • You have severe kidney disease that requires dialysis
  • You have had or are planning to have a blood vessel procedure on the affected leg within 30 days of the trial
  • You have taken part in another clinical trial involving an investigational treatment within the last 30 days
  • You have had an active problem with alcohol or substance misuse within the last 3 months
  • You are currently pregnant or breastfeeding
  • The trial doctor has identified other reasons that may make participation unsuitable (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 7342550366

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Eluciderm Inc
Registry
ClinicalTrials.gov
Start date
10 November 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage Area Reduction (PAR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov